Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,200 across all filing types
Latest filing 2023-07-18 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a compliance communication under SEBI regulations regarding the issuance of a duplicate share certificate to a shareholder. It includes details about the shareholder, old and new certificate numbers, and proof of dispatch. There is no financial data, no discussion of financial results, no management commentary, and no mention of a report being attached or published. The document is a regulatory compliance notice related to share certificates, which does not fit into financial reports or meeting materials. It is best classified as a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-07-18 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a compliance communication under SEBI regulations regarding the issuance of duplicate share certificates due to a shareholder's name change. It includes details about the old and new share certificates and confirms dispatch of the Letter of Confirmation. There is no financial data, no report or presentation, and no mention of voting results or management changes. This is a regulatory compliance announcement related to share certificate issuance, which does not fit into financial reports or other specific categories. Therefore, it falls under Regulatory Filings (RNS) as a general regulatory announcement.
2023-07-12 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a formal letter addressed to stock exchanges announcing the allotment of shares to employees under a stock option plan. It specifies the increase in paid-up share capital and the number of equity shares after allotment. There is no financial data, report, or detailed analysis present. The content clearly relates to a change in the company's capital structure due to share allotment. Therefore, this document fits the category of Share Issue/Capital Change (SHA). The document length is short and focused solely on this announcement, confirming it is not a full report or other filing type.
2023-07-07 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Stelis Biopharma has entered into a binding term sheet with Syngene International Limited to divest a manufacturing facility. It details the transaction terms, approvals, and business implications. There are no financial statements, regulatory certifications, or detailed financial performance data. The document is an announcement of a capital transaction (divestment of an asset) and financing consideration. This fits the category of Capital/Financing Update (CAP). The document length is 5555 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the appropriate classification is CAP with high confidence.
2023-07-04 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a notification regarding the issuance of a duplicate share certificate to a shareholder, including details of the shareholder and certificate numbers. It references compliance with SEBI regulations and includes communication with the Registrar and Transfer Agent. There is no financial data, earnings information, or report attached. The document is an announcement related to share certificates and shareholder records, not a financial report or management information. It fits best under Regulatory Filings (RNS) as a general regulatory announcement about share certificate issuance and compliance with listing obligations.
2023-06-29 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding a shareholder's request for issuance of a duplicate share certificate due to loss of original securities. It references compliance with SEBI regulations and includes details about the shareholder and share certificates. The content is about a procedural update related to share certificates and does not contain financial data, earnings, management changes, or report publications. It is not a report or announcement of financial results but a regulatory compliance notification related to shareholding records. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.